COVID-19疫苗接种后的长期甲状腺结局:基于TriNetX网络2 333 496例患者的队列研究
该回顾性队列研究利用TriNetX数据库纳入2022年1月1日至2023年12月31日间的1 166 748例疫苗接种者和1 166 748例未接种者,经倾向性评分匹配后分析新发亚急性甲状腺炎、甲状腺功能亢进症和甲状腺功能减退症的风险。结果显示亚急性甲状腺炎风险不变,接种后3至9个月甲状腺功能亢进症风险显著降低(HR 0.65-0.89),但6至12个月甲状腺功能减退症风险显著增加(HR 1.14-1.30)。
要点
- 接种后3至9个月甲状腺功能亢进症风险显著降低(HR 0.65-0.89),12个月时不再显著(HR 0.99)。
- 接种后6至12个月甲状腺功能减退症风险显著增加(HR 1.14-1.30)。
- mRNA疫苗接种者12个月时甲状腺功能亢进症和甲状腺功能减退症风险均显著升高(HR 1.16-2.13)。
核心结论
- COVID-19疫苗接种与甲状腺功能亢进症风险降低及甲状腺功能减退症风险增加相关,提示需要持续监测甲状腺功能。
研究设计与样本
- 回顾性队列研究,使用TriNetX数据库,纳入2022年1月1日至2023年12月31日间的1 166 748例疫苗接种者和1 166 748例未接种者,采用倾向性评分匹配平衡基线特征。
主要发现
- 亚急性甲状腺炎风险不变(95%CI包含1)。
- 接种后3至9个月甲状腺功能亢进症风险显著降低(HR 0.65-0.89,所有95%CI低于1),12个月时该趋势不显著(HR 0.99;95%CI 0.92-1.06)。
- 接种后6至12个月甲状腺功能减退症风险显著增加(HR 1.14-1.30,所有95%CI高于1)。
- mRNA疫苗接种者12个月时甲状腺功能亢进症和甲状腺功能减退症风险均显著升高(HR 1.16-2.13)。
临床怎么用
- 原文结论指出COVID-19疫苗接种与甲状腺功能亢进症风险降低及甲状腺功能减退症风险增加相关,强调需要持续监测甲状腺功能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Reports on long-term thyroid dysfunction following COVID-19 vaccination are limited. Understanding the risk of subacute thyroiditis, hyperthyroidism, and hypothyroidism in vaccinated individuals is crucial for postvaccination monitoring. OBJECTIVE: This study evaluated the risk of thyroid dysfunction in individuals vaccinated against COVID-19 compared to unvaccinated individuals, using a large cohort. METHODS: We conducted a retrospective cohort study from January 1, 2022, to December 31, 2023, using the TriNetX database, including 1 166 748 vaccinated and 1 166 748 unvaccinated individuals. Propensity score matching was used to balance baseline characteristics. The primary outcomes were new diagnoses of subacute thyroiditis, hyperthyroidism, and hypothyroidism. RESULTS: The risk of subacute thyroiditis remained unchanged (95% CIs included 1). A significant reduction in hyperthyroidism risk was observed from 3 to 9 months postvaccination (hazard ratios [HRs]: 0.65-0.89, all 95% CIs below 1), but this trend was not significant at 12 months (HR: 0.99; 95% CI: 0.92-1.06). In contrast, the risk of hypothyroidism significantly increased from 6 to 12 months postvaccination (HR: 1.14-1.30, all 95% CIs above 1). Among mRNA vaccine recipients, the risk of both hyperthyroidism and hypothyroidism was significantly elevated at 12 months (HR: 1.16-2.13). CONCLUSION: COVID-19 vaccination was associated with a reduced risk of hyperthyroidism and an increased risk of hypothyroidism, highlighting the need for ongoing thyroid function monitoring.
引用
- Cheng KL, Yu WS, Wang YH, et al. Long-Term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2 333 496 Patients From the TriNetX Network. J Clin Endocrinol Metab. 2025. PMID: 39883558. doi:10.1210/clinem/dgaf064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。